What Iterative Health Announced About Its 77 Million Dollar Series C

Iterative Health said on 30 April 2026 that it closed a 77 million dollar Series C led by Intrepid Growth Partners and GV, with new investors EDBI and a family office joining existing investors including Insight Partners and Obvious Ventures. The company describes itself as a healthcare technology and services company accelerating clinical research by combining centralised operations, expert staffing, its own AI technology and trial expertise into a multispecialty research network, and says the money funds expansion into cardiology and obesity beyond gastroenterology and hepatology. It reports site activation twice as fast, cutting startup timelines by up to three months, and enrollment rates three times higher, averaging more than two inflammatory bowel disease patients randomised every business day, and notes that nearly 90 percent of United States trials miss enrollment targets on time. Its AI product is named SKOUT.

Why the Iterative Health Series C Matters to Trial Sponsors

The interesting shift is that this company started as endoscopy AI and is now a research site network that happens to own AI, and the funding is explicitly for buying into new therapy areas. For a sponsor that is a real option, because a network with its own staff can be held to an activation date in a way a loose group of sites cannot. It also means the AI claim and the operational claim need separating: three times enrollment could come from the algorithm finding patients or from paying coordinators to work harder, and the announcement does not split them. Two patients randomised a business day is a useful, checkable figure in a disease area where one a week is common.

Where the Iterative Health Update Comes From

Iterative Health is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Iterative Health original source.

How We Would Research the Iterative Health Series C

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would ask Iterative Health to split the enrollment gain between the SKOUT screening step and the staffing and operations model.
  2. Then we would ask for activation dates actually hit across its last ten studies rather than an average multiple.
  3. We would check what happens to a study if the company sells or closes an acquired site mid-trial, since it has been buying sites through 2026.